impact factor

D. Specific diseases


Treat-to-target in systemic lupus erythematosus: where are we today?

, , , , , , , , , , ,


2012 Vol.30, N°4 ,Suppl.73
PI 0112, PF 0115
D. Specific diseases

Free to view
(click on article PDF icon to read the article)

PMID: 23072706 [PubMed]

Received: 14/09/2012
Accepted : 19/09/2012
In Press: 20/11/2012
Published: 20/11/2012


Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-to-target approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.

Rheumatology Article